Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
199.26
-0.01 (-0.01%)
Sep 10, 2024, 10:13 AM EDT - Market open
Biogen Employees
Biogen had 7,570 employees as of December 31, 2023. The number of employees decreased by 1,155 or -13.24% compared to the previous year.
Employees
7,570
Change (1Y)
-1,155
Growth (1Y)
-13.24%
Revenue / Employee
$1,277,675
Profits / Employee
$153,052
Market Cap
29.03B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7,570 | -1,155 | -13.24% |
Dec 31, 2022 | 8,725 | -885 | -9.21% |
Dec 31, 2021 | 9,610 | 510 | 5.60% |
Dec 31, 2020 | 9,100 | 1,700 | 22.97% |
Dec 31, 2019 | 7,400 | -400 | -5.13% |
Dec 31, 2018 | 7,800 | 500 | 6.85% |
Dec 31, 2017 | 7,300 | -100 | -1.35% |
Dec 31, 2016 | 7,400 | 50 | 0.68% |
Dec 31, 2015 | 7,350 | -200 | -2.65% |
Dec 31, 2014 | 7,550 | 700 | 10.22% |
Dec 31, 2013 | 6,850 | 900 | 15.13% |
Dec 31, 2012 | 5,950 | 950 | 19.00% |
Dec 31, 2011 | 5,000 | 150 | 3.09% |
Dec 31, 2010 | 4,850 | 100 | 2.11% |
Dec 31, 2009 | 4,750 | 50 | 1.06% |
Dec 31, 2008 | 4,700 | 400 | 9.30% |
Dec 31, 2007 | 4,300 | 550 | 14.67% |
Dec 31, 2006 | 3,750 | 410 | 12.28% |
Dec 31, 2005 | 3,340 | -926 | -21.71% |
Dec 31, 2004 | 4,266 | 539 | 14.46% |
Feb 20, 2004 | 3,727 | 2,732 | 274.57% |
Jan 31, 2003 | 995 | 303 | 43.79% |
Jan 31, 2002 | 692 | 199 | 40.37% |
Jan 31, 2001 | 493 | 86 | 21.13% |
Jan 31, 2000 | 407 | 42 | 11.51% |
Jan 31, 1999 | 365 | 26 | 7.67% |
Dec 31, 1997 | 339 | 71 | 26.49% |
Dec 31, 1996 | 268 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Koninklijke Philips | 69,656 |
Centene | 67,000 |
Cardinal Health | 48,900 |
Mettler-Toledo International | 17,300 |
ResMed | 9,980 |
DexCom | 9,600 |
Veeva Systems | 7,172 |
Moderna | 5,600 |
BIIB News
- 2 days ago - Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment - CNBC
- 5 days ago - Biogen Inc.'s (BIIB) Morgan Stanley's 22nd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 6 days ago - Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA - GlobeNewsWire
- 19 days ago - UK patients unlikely to get access to Eisai-Biogen's Alzheimer's drug - Reuters
- 23 days ago - Biogen: Q2 Earnings, Share Price May Have Bottomed Out As CEO Makes Mark - Seeking Alpha
- 4 weeks ago - OpenFold AI Research Consortium Welcomes Six New Members: Astex, Biogen, Congruence, Polaris Quantum, Psivant, and SandboxAQ - Business Wire
- 5 weeks ago - Biogen Inc. (BIIB) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Drug maker Biogen boosts profit outlook and tops Q2 profit estimate - Market Watch